RxDoctor Payments DataLook up a doctor →

Michael Manetas, MD

Gastroenterology · Richmond, VANPI 1275535213

Payments from drug & device makers

$125,457in general payments, 2019–2025

Across 807 payments — averaging $155.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$55K
  • AbbVie$29K
  • Phathom Pharmaceuticals, Inc.$21K
  • Ironwood Pharmaceuticals, Inc$13K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • plus $5K from 30 others

What the payments were for

  • Consulting fees$170%
  • Speaking & faculty fees$97,67378%
  • Travel & lodging$10,2578%
  • Food & beverage$17,39514%
  • Education$1150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$125,457 in reported general payments places this provider in the 90th percentile of 473 gastroenterology providers in Virginia.

See all gastroenterology providers in Virginia

Medicare billing

Part B allowed, 2024
$152,089
Medicare patients
520
Services billed
1,076

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab32$852,862
CreonLipase/Protease/Amylase30$167,820
LinzessLinaclotide87$81,993
ZenpepLipase/Protease/Amylase14$56,114
TrulancePlecanatide18$13,103
Mesalamine ErMesalamine31$11,243
Dexlansoprazole DrDexlansoprazole43$10,059
Lubiprostone68$7,438
Famotidine527$7,187
Colestipol Hcl51$6,555
AprisoMesalamine13$6,527
Sucralfate94$6,242
Mesalamine31$5,885
Pantoprazole Sodium303$3,896
ClenpiqSod Picosulf/Mag Ox/Citric Ac22$3,788

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$54,998$852,86232 claims
AbbVieCreon, Linzess$29,072$249,813117 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance, Apriso$1,419$19,62931 claims
Ferring Pharmaceuticals Inc.Clenpiq$97$3,78822 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 473 gastroenterology providers in Virginia.

Other gastroenterology in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →